Does the media prefer AVXL or SERA?

In the previous week, Anavex Life Sciences and Anavex Life Sciences both had 8 articles in the media. Anavex Life Sciences' average media sentiment score of 0.70 beat Sera Prognostics' score of -0.16 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer SGMT or SERA?

In the previous week, Sagimet Biosciences had 15 more articles in the media than Sera Prognostics. MarketBeat recorded 23 mentions for Sagimet Biosciences and 8 mentions for Sera Prognostics. Sagimet Biosciences' average media sentiment score of 0.49 beat Sera Prognostics' score of -0.16 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 8 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor SERA or MYGN?

In the previous week, Sera Prognostics and Sera Prognostics both had 8 articles in the media. Myriad Genetics' average media sentiment score of 0.54 beat Sera Prognostics' score of -0.16 indicating that Myriad Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Myriad Genetics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is IRD or SERA more profitable?

Opus Genetics has a net margin of -1,091.82% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Opus Genetics -1,091.82% -338.88% -150.13% Sera Prognostics -47,475.72% -46.71% -34.06%

Does the media prefer IRD or SERA?

In the previous week, Opus Genetics had 17 more articles in the media than Sera Prognostics. MarketBeat recorded 25 mentions for Opus Genetics and 8 mentions for Sera Prognostics. Opus Genetics' average media sentiment score of 1.05 beat Sera Prognostics' score of -0.16 indicating that Opus Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor SERA or IMRX?

In the previous week, Immuneering had 3 more articles in the media than Sera Prognostics. MarketBeat recorded 11 mentions for Immuneering and 8 mentions for Sera Prognostics. Immuneering's average media sentiment score of 1.18 beat Sera Prognostics' score of -0.16 indicating that Immuneering is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Immuneering 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sera Prognostics (SERA) Competitors

$1.96 -0.05 (-2.49%)

Closing price 04:00 PM Eastern

Extended Trading

$1.96 +0.01 (+0.26%)

As of 07:57 PM Eastern

Compare

SERA vs. AVXL, SGMT, MYGN, IRD, and IMRX

Should you buy Sera Prognostics stock or one of its competitors? Sera Prognostics's main competitors and comparable companies include Anavex Life Sciences (AVXL), Sagimet Biosciences (SGMT), Myriad Genetics (MYGN), Opus Genetics (IRD), and Immuneering (IMRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sera Prognostics compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Anavex Life Sciences has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Anavex Life Sciences' return on equity of -32.73% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-32.73%	-30.15%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Anavex Life Sciences currently has a consensus target price of $21.33, indicating a potential upside of 562.53%. Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 180.61%. Given Anavex Life Sciences' higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Sera Prognostics has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A
Sera Prognostics	$80K	959.42	-$31.93M	-$0.65	N/A

Anavex Life Sciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

In the previous week, Anavex Life Sciences and Anavex Life Sciences both had 8 articles in the media. Anavex Life Sciences' average media sentiment score of 0.70 beat Sera Prognostics' score of -0.16 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Anavex Life Sciences beats Sera Prognostics on 9 of the 15 factors compared between the two stocks.

How does Sera Prognostics compare to Sagimet Biosciences?

Sagimet Biosciences (NASDAQ:SGMT) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 11.5% of Sagimet Biosciences shares are held by company insiders. Comparatively, 11.3% of Sera Prognostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sagimet Biosciences currently has a consensus target price of $29.17, suggesting a potential upside of 176.46%. Sera Prognostics has a consensus target price of $5.50, suggesting a potential upside of 180.61%. Given Sera Prognostics' stronger consensus rating and higher possible upside, analysts clearly believe Sera Prognostics is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Sagimet Biosciences has a beta of 3.37, suggesting that its share price is 237% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Sagimet Biosciences has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sagimet Biosciences' return on equity of -31.96% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Sera Prognostics has lower revenue, but higher earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	171.86	-$51.04M	-$1.34	N/A
Sera Prognostics	$80K	959.42	-$31.93M	-$0.65	N/A

In the previous week, Sagimet Biosciences had 15 more articles in the media than Sera Prognostics. MarketBeat recorded 23 mentions for Sagimet Biosciences and 8 mentions for Sera Prognostics. Sagimet Biosciences' average media sentiment score of 0.49 beat Sera Prognostics' score of -0.16 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	8 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Sagimet Biosciences beats Sera Prognostics on 10 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to Myriad Genetics?

Sera Prognostics (NASDAQ:SERA) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

In the previous week, Sera Prognostics and Sera Prognostics both had 8 articles in the media. Myriad Genetics' average media sentiment score of 0.54 beat Sera Prognostics' score of -0.16 indicating that Myriad Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Myriad Genetics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Sera Prognostics currently has a consensus price target of $5.50, indicating a potential upside of 180.61%. Myriad Genetics has a consensus price target of $5.38, indicating a potential upside of 77.39%. Given Sera Prognostics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Sera Prognostics is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Myriad Genetics	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

Sera Prognostics has higher earnings, but lower revenue than Myriad Genetics. Sera Prognostics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	959.42	-$31.93M	-$0.65	N/A
Myriad Genetics	$824.50M	0.35	-$365.90M	-$1.19	N/A

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by company insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Myriad Genetics has a net margin of -13.96% compared to Sera Prognostics' net margin of -47,475.72%. Myriad Genetics' return on equity of -16.09% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Myriad Genetics	-13.96%	-16.09%	-8.10%

Sera Prognostics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

Summary

Myriad Genetics beats Sera Prognostics on 8 of the 15 factors compared between the two stocks.

How does Sera Prognostics compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Opus Genetics has a net margin of -1,091.82% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Opus Genetics presently has a consensus price target of $10.69, indicating a potential upside of 196.19%. Sera Prognostics has a consensus price target of $5.50, indicating a potential upside of 180.61%. Given Opus Genetics' stronger consensus rating and higher possible upside, research analysts clearly believe Opus Genetics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Opus Genetics had 17 more articles in the media than Sera Prognostics. MarketBeat recorded 25 mentions for Opus Genetics and 8 mentions for Sera Prognostics. Opus Genetics' average media sentiment score of 1.05 beat Sera Prognostics' score of -0.16 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Sera Prognostics has lower revenue, but higher earnings than Opus Genetics. Sera Prognostics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	21.01	-$49.59M	-$1.35	N/A
Sera Prognostics	$80K	959.42	-$31.93M	-$0.65	N/A

Opus Genetics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Opus Genetics beats Sera Prognostics on 9 of the 16 factors compared between the two stocks.

How does Sera Prognostics compare to Immuneering?

Sera Prognostics (NASDAQ:SERA) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Immuneering had 3 more articles in the media than Sera Prognostics. MarketBeat recorded 11 mentions for Immuneering and 8 mentions for Sera Prognostics. Immuneering's average media sentiment score of 1.18 beat Sera Prognostics' score of -0.16 indicating that Immuneering is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immuneering	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sera Prognostics currently has a consensus price target of $5.50, suggesting a potential upside of 180.61%. Immuneering has a consensus price target of $17.50, suggesting a potential upside of 245.85%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Sera Prognostics has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	959.42	-$31.93M	-$0.65	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A

Sera Prognostics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by insiders. Comparatively, 14.9% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Immuneering has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Immuneering's return on equity of -27.15% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Immuneering	N/A	-27.15%	-25.75%

Summary

Immuneering beats Sera Prognostics on 11 of the 16 factors compared between the two stocks.

Get Sera Prognostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SERA vs. The Competition

Export

Metric	Sera Prognostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$78.71M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-2.93	6.29	211.09	21.74
Price / Sales	959.42	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	1.29	16.78	12.91	6.24
Net Income	-$31.93M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-5.31%	1.74%	1.12%	1.07%
1 Month Performance	-1.01%	1.60%	1.79%	1.03%
1 Year Performance	-12.89%	56.43%	67.69%	20.77%

Sera Prognostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SERA Sera Prognostics	2.6754 of 5 stars	$1.96 -2.5%	$5.50 +180.6%	-12.6%	$78.71M	$80K	N/A	120	News Coverage Earnings Report
AVXL Anavex Life Sciences	1.5386 of 5 stars	$3.51 +3.5%	$21.33 +507.8%	-69.0%	$314.16M	N/A	N/A	40
SGMT Sagimet Biosciences	2.828 of 5 stars	$9.52 -0.5%	$25.17 +164.4%	-3.1%	$311.84M	N/A	N/A	8	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
MYGN Myriad Genetics	3.4003 of 5 stars	$3.22 -0.9%	$5.38 +66.9%	-46.0%	$310.86M	$824.50M	N/A	2,700
IRD Opus Genetics	3.0739 of 5 stars	$3.88 +6.0%	$10.69 +175.6%	+238.2%	$302.49M	$14.20M	N/A	14	Trending News Analyst Upgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SERA) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sera Prognostics (SERA) Competitors

SERA vs. AVXL, SGMT, MYGN, IRD, and IMRX

How does Sera Prognostics compare to Anavex Life Sciences?

Summary

How does Sera Prognostics compare to Sagimet Biosciences?

Summary

How does Sera Prognostics compare to Myriad Genetics?

Summary

How does Sera Prognostics compare to Opus Genetics?

Summary

How does Sera Prognostics compare to Immuneering?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sera Prognostics (SERA) Competitors

SERA vs. AVXL, SGMT, MYGN, IRD, and IMRX

How does Sera Prognostics compare to Anavex Life Sciences?

Is AVXL or SERA more profitable?

Do analysts recommend AVXL or SERA?

Which has better earnings & valuation, AVXL or SERA?

Which has more volatility & risk, AVXL or SERA?

Does the media prefer AVXL or SERA?

Do institutionals & insiders believe in AVXL or SERA?

Summary

How does Sera Prognostics compare to Sagimet Biosciences?

Do insiders and institutionals hold more shares of SGMT or SERA?

Do analysts recommend SGMT or SERA?

Which has more volatility & risk, SGMT or SERA?

Is SGMT or SERA more profitable?

Which has higher valuation & earnings, SGMT or SERA?

Does the media prefer SGMT or SERA?

Summary

How does Sera Prognostics compare to Myriad Genetics?

Does the media favor SERA or MYGN?

Do analysts rate SERA or MYGN?

Which has higher valuation and earnings, SERA or MYGN?

Do institutionals & insiders believe in SERA or MYGN?

Is SERA or MYGN more profitable?

Which has more volatility and risk, SERA or MYGN?

Summary

How does Sera Prognostics compare to Opus Genetics?

Is IRD or SERA more profitable?

Do analysts recommend IRD or SERA?

Does the media prefer IRD or SERA?

Which has better earnings and valuation, IRD or SERA?

Which has more volatility and risk, IRD or SERA?

Do insiders & institutionals believe in IRD or SERA?

Summary

How does Sera Prognostics compare to Immuneering?

Does the media favor SERA or IMRX?

Do analysts recommend SERA or IMRX?

Which has stronger earnings and valuation, SERA or IMRX?

Which has more volatility & risk, SERA or IMRX?

Do insiders and institutionals hold more shares of SERA or IMRX?

Is SERA or IMRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools